David do Carmo Malvar1, Raquel Teixeira Ferreira2, Raphael Andrade de Castro2, Ligia Lins de Castro2, Antonio Carlos Carreira Freitas3, Elson Alves Costa4, Iziara Ferreira Florentino4, João Carlos Martins Mafra3, Glória Emília Petto de Souza5, Frederico Argollo Vanderlinde2. 1. Universidade Federal Rural do Rio de Janeiro, Instituto de Biologia, Departamento de Ciências Fisiológicas, Seropédica, RJ, Brazil; Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP, Departamento de Física e Química, Ribeirão Preto, SP, Brazil. Electronic address: dcmalvar@gmail.com. 2. Universidade Federal Rural do Rio de Janeiro, Instituto de Biologia, Departamento de Ciências Fisiológicas, Seropédica, RJ, Brazil. 3. Universidade Federal do Rio de Janeiro, Núcleo de Pesquisas de Produtos Naturais, Cidade Universitária, Rio de Janeiro, RJ, Brazil. 4. Universidade Federal de Goiás, Instituto de Ciências Biológicas, Departamento de Ciências Fisiológicas, Goiânia, GO, Brazil. 5. Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP, Departamento de Física e Química, Ribeirão Preto, SP, Brazil.
Abstract
AIMS: Heterocyclic pyrazole derivative has been described for the treatment of pain and inflammatory diseases. This study evaluated the in vivo, antinociceptive, anti-inflammatory and antipyretic effects of 1.5-diphenyl-1H-Pyrazole-3-carbohydrazide (1.5-DHP) and the in vivo or in vitro mechanism of action. MAIN METHODS: Acetic acid-induced writhing, hot-plate and formalin-induced nociception tests were used to evaluate the antinociceptive effect, while the rota-rod test was used to assess the motor activity. Croton oil-induced ear edema and carrageenan-induced peritonitis tests were used to investigate the anti-inflammatory effect of 1.5-DHP. The antipyretic effect was assessed using the LPS-induced fever model. The mechanism of action was evaluated by PGE2 and TNF-α measurement and cyclooxygenase inhibition assay. KEY FINDINGS: Oral administration (p.o.) of 1.5-DHP (1, 3, 10 mg/kg) caused a dose-related inhibition of the acetic acid-induced writhing, however the highest dose was not effective on the hot-plate and rota-rod. In the formalin-induced nociception, 1.5-DHP (10mg/kg, p.o.) inhibited only the late phase of nociception. This same dose of 1.5-DHP also reduced the croton oil-induced ear edema. 1.5-DHP (3, 10, 30 mg/kg, p.o.) produced a dose-related reduction of leukocyte migration on the carrageenan-induced peritonitis. 1.5-DHP (60 mg/kg, p.o.) reduced the fever and the increase of PGE2 concentration in the cerebrospinal fluid induced by LPS. 1.5-DHP inhibited both COXs in vitro. Finally, 1.5-DHP (10 mg/kg, p.o.) reduced the TNF-α concentration in peritoneal exudates after carrageenan injection. SIGNIFICANCE: These results indicate that 1.5-DHP produces anti-inflammatory, antinociceptive and antipyretic effects by PGE2 synthesis reduction through COX-1/COX-2 inhibition and by TNF-α synthesis/release inhibition.
AIMS: Heterocyclic pyrazole derivative has been described for the treatment of pain and inflammatory diseases. This study evaluated the in vivo, antinociceptive, anti-inflammatory and antipyretic effects of 1.5-diphenyl-1H-Pyrazole-3-carbohydrazide (1.5-DHP) and the in vivo or in vitro mechanism of action. MAIN METHODS:Acetic acid-induced writhing, hot-plate and formalin-induced nociception tests were used to evaluate the antinociceptive effect, while the rota-rod test was used to assess the motor activity. Croton oil-induced ear edema and carrageenan-induced peritonitis tests were used to investigate the anti-inflammatory effect of 1.5-DHP. The antipyretic effect was assessed using the LPS-induced fever model. The mechanism of action was evaluated by PGE2 and TNF-α measurement and cyclooxygenase inhibition assay. KEY FINDINGS: Oral administration (p.o.) of 1.5-DHP (1, 3, 10 mg/kg) caused a dose-related inhibition of the acetic acid-induced writhing, however the highest dose was not effective on the hot-plate and rota-rod. In the formalin-induced nociception, 1.5-DHP (10mg/kg, p.o.) inhibited only the late phase of nociception. This same dose of 1.5-DHP also reduced the croton oil-induced ear edema. 1.5-DHP (3, 10, 30 mg/kg, p.o.) produced a dose-related reduction of leukocyte migration on the carrageenan-induced peritonitis. 1.5-DHP (60 mg/kg, p.o.) reduced the fever and the increase of PGE2 concentration in the cerebrospinal fluid induced by LPS. 1.5-DHP inhibited both COXs in vitro. Finally, 1.5-DHP (10 mg/kg, p.o.) reduced the TNF-α concentration in peritoneal exudates after carrageenan injection. SIGNIFICANCE: These results indicate that 1.5-DHP produces anti-inflammatory, antinociceptive and antipyretic effects by PGE2 synthesis reduction through COX-1/COX-2 inhibition and by TNF-α synthesis/release inhibition.
Authors: Fariba Peytam; Mehdi Adib; Reihaneh Shourgeshty; Maryam Mohammadi-Khanaposhtani; Mehdi Jahani; Somaye Imanparast; Mohammad Ali Faramarzi; Mohammad Mahdavi; Ali Akbar Moghadamnia; Hossein Rastegar; Bagher Larijani Journal: Mol Divers Date: 2019-03-02 Impact factor: 2.943
Authors: Iziara F Florentino; Daiany P B da Silva; José Luís R Martins; Taciane S da Silva; Fernanda C A Santos; Carlos R Tonussi; Géssica A Vasconcelos; Boniek G Vaz; Luciano M Lião; Ricardo Menegatti; Elson A Costa Journal: Inflammopharmacology Date: 2016-09-26 Impact factor: 4.473
Authors: Daniel C Batista; Daiany P B Silva; Iziara F Florentino; Carina S Cardoso; Merita P Gonçalves; Marize C Valadares; Luciano M Lião; Germán Sanz; Boniek G Vaz; Elson A Costa; Ricardo Menegatti Journal: Inflammopharmacology Date: 2017-08-20 Impact factor: 4.473
Authors: Vera S Glukhacheva; Sergey G Il'yasov; Igor V Kazantsev; Elena O Shestakova; Dmitri S Il'yasov; Ilia V Eltsov; Andrey A Nefedov; Yuri V Gatilov Journal: ACS Omega Date: 2021-03-17